| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/11/2007 | US20070009523 Polypeptide variants with altered effector function |
| 01/11/2007 | US20070009522 administering to an Rh-negative individual in need of an anti-Rh(D) monoclonal antibody, wherein monoclonal antibody exhibits a Fc gamma RTIII-type ADCC ( antibody-dependent cell-mediated cytotoxicity (ADCC) assays) level greater than 80% relative to a reference polyclonal anti-Rh(D) human antibody |
| 01/11/2007 | US20070009521 Human tumor necrosis factor TR21 and methods based thereon |
| 01/11/2007 | US20070009520 Osteoclastogenesis inhibitory factor-binding molecule (OBM) specific immunoglobulin for use inhibiting osteoclast inhibitory factor (OCIF) binding activity and treating bone disorders |
| 01/11/2007 | US20070009519 Immunoregulatory Antibodies and Uses Thereof |
| 01/11/2007 | US20070009518 Methods for treating fibrotic conditions |
| 01/11/2007 | US20070009517 Method of inducing immune tolerance |
| 01/11/2007 | US20070009516 Immune response-associated proteins |
| 01/11/2007 | US20070009515 Inflammatory skin disease-related slurp-2 gene and utilization thereof |
| 01/11/2007 | US20070009514 Prostaglandin receptor ep1 |
| 01/11/2007 | US20070009513 Novel method of screening |
| 01/11/2007 | US20070009512 Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains |
| 01/11/2007 | US20070009511 Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules |
| 01/11/2007 | US20070009510 Monoclonal antibodies against ricin toxin and methods of making and using thereof |
| 01/11/2007 | US20070009509 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor |
| 01/11/2007 | US20070009508 untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing the antigen; for cancers, autoimmune or inflammatory disorders |
| 01/11/2007 | US20070009507 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis |
| 01/11/2007 | US20070009497 Dendritic cell expanded T suppressor cells and methods of use thereof |
| 01/11/2007 | US20070009489 Mutant Salmonella species with genetically engineered MSBB gene, expresses altered lipid, has reduced inductino of tumor necrosis factor and increased sensitivity to chelating agents; as antitumor agent |
| 01/11/2007 | US20070009488 Feline granulocyte macrophage colony stimulating factor nucleic acid molecules |
| 01/11/2007 | US20070009487 Minimal promoters and uses thereof |
| 01/11/2007 | US20070009482 Stimulant of immunology response; viricides |
| 01/11/2007 | US20070009469 Treatment of skin, and wound repair, with thymosin beta 4 |
| 01/11/2007 | US20070009433 14094, a novel human trypsin family member and uses thereof |
| 01/11/2007 | CA2848662A1 Il-12/p40 binding proteins |
| 01/11/2007 | CA2656741A1 Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| 01/11/2007 | CA2617539A1 Phosphospecific chemokine receptor antibodies |
| 01/11/2007 | CA2614080A1 Anti-ccr7 receptor antibodies for the treatment of cancer |
| 01/11/2007 | CA2614076A1 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
| 01/11/2007 | CA2614046A1 Methods and compositions with enhanced therapeutic activity |
| 01/11/2007 | CA2614006A1 Stable aqueous systems comprising proteins |
| 01/11/2007 | CA2613836A1 F11 receptor (f11r) antagonists as therapeutic agents |
| 01/11/2007 | CA2613818A1 Anti-il-23 antibodies, compositions, methods and uses |
| 01/11/2007 | CA2613749A1 Methods and compositions for diagnosis and treatment of viral and bacterial infections |
| 01/11/2007 | CA2613691A1 Anticoagulation agent and uses thereof |
| 01/11/2007 | CA2613481A1 Process for attaching effector molecules to proteins |
| 01/11/2007 | CA2613057A1 Anti-malaria vaccine |
| 01/11/2007 | CA2613040A1 Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| 01/11/2007 | CA2612241A1 Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| 01/11/2007 | CA2612239A1 Il-12/p40 binding proteins |
| 01/10/2007 | EP1741792A1 Novel ligand of g-protein-conjugated receptor protein and use thereof |
| 01/10/2007 | EP1741789A1 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines |
| 01/10/2007 | EP1741785A1 Porcine circoviruses, nucleic acids, polypeptides and vaccines |
| 01/10/2007 | EP1741784A1 85kDa neisserial antigen |
| 01/10/2007 | EP1741783A1 Human antiamyloid beta peptide antibody and antibody fragment thereof |
| 01/10/2007 | EP1741782A2 Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| 01/10/2007 | EP1741779A2 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity |
| 01/10/2007 | EP1741720A1 Modified DNA molecule, recombinant containing the same, and uses thereof |
| 01/10/2007 | EP1741718A2 Expression of lipoproteins |
| 01/10/2007 | EP1741449A1 Preventive and/or remedy for cancer |
| 01/10/2007 | EP1741443A2 Combination meningitidis B/C vaccines |
| 01/10/2007 | EP1741442A2 Neisseria meningitidis combination vaccines |
| 01/10/2007 | EP1741438A1 Pharmaceutical preparation containing bacterial cell wall skeleton component |
| 01/10/2007 | EP1740954A1 Mass spectrometry of antibody conjugates |
| 01/10/2007 | EP1740946A2 Human monoclonal antibodies against cd20 |
| 01/10/2007 | EP1740712A2 Lactoferrin cleavage of neisserial proteins |
| 01/10/2007 | EP1740619A1 Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| 01/10/2007 | EP1740618A1 Compositions and methods for enhancing nk cell activity |
| 01/10/2007 | EP1740617A1 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| 01/10/2007 | EP1740616A1 Anti-tfr antibody. |
| 01/10/2007 | EP1740615A2 Humanized anti-tgf-beta antibodies |
| 01/10/2007 | EP1740604A2 Td antigens |
| 01/10/2007 | EP1740602A2 A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5 |
| 01/10/2007 | EP1740224A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use |
| 01/10/2007 | EP1740221A2 Methods and compositions for the treatment of polycystic diseases |
| 01/10/2007 | EP1740220A2 Non-natural ribonuclease conjugates as cytotoxic agents |
| 01/10/2007 | EP1740219A2 Medical device with coating for capturing genetically-altered cells and methods of using same |
| 01/10/2007 | EP1740217A2 Meningococcal conjugate vaccination |
| 01/10/2007 | EP1740210A2 Irta-5 antibodies and their uses |
| 01/10/2007 | EP1740209A2 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| 01/10/2007 | EP1740208A2 Monoclonal antibodies specific for human ox40l (cd134l) |
| 01/10/2007 | EP1740207A2 Antigen delivery vectors and constructs |
| 01/10/2007 | EP1740206A2 Phep, an amino acid permease of staphylococcus aureus |
| 01/10/2007 | EP1740205A1 Vaccination against malignant melanoma using bcg and/or vaccinia |
| 01/10/2007 | EP1740193A2 Macromolecule-containing sustained release intraocular implants and related methods |
| 01/10/2007 | EP1740182A2 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| 01/10/2007 | EP1740167A2 Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
| 01/10/2007 | EP1485129B1 Nanostructures containing pilin protein |
| 01/10/2007 | EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/10/2007 | EP1416885B1 Devices for delivery of therapeutic agents with variable release profile |
| 01/10/2007 | EP1322330B1 Modulation of allergic response |
| 01/10/2007 | EP1280551B1 Vaccines against hiv infection |
| 01/10/2007 | EP1113777B1 Novel hepatitis c virus peptides and uses thereof |
| 01/10/2007 | EP1078060B1 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 01/10/2007 | EP1017723B1 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 01/10/2007 | EP0918796B1 Monoclonal antibody which agglutinates e. coli having the cs4-cfa/i family protein |
| 01/10/2007 | EP0914440B1 Nucleic acid vaccination for parvoviral infections |
| 01/10/2007 | EP0812357B1 A method for making heteromultimeric polypeptides |
| 01/10/2007 | CN1894695A Altered antibodies having improved antigen-binding affinity |
| 01/10/2007 | CN1894410A DNA-sequence and recombinant production of group 4 major allergens from cereals |
| 01/10/2007 | CN1894408A Metabolic protein for weed-control agent, its gene, and its use |
| 01/10/2007 | CN1894406A Antibody composition-producing cell |
| 01/10/2007 | CN1894399A Production of diphtheria toxin |
| 01/10/2007 | CN1894275A Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| 01/10/2007 | CN1894026A Cryogranulation and storage method for active pharmaceutical agents |
| 01/10/2007 | CN1893989A Crosslinked hyaluronic acid compositions for tissue augmentation |
| 01/10/2007 | CN1893979A Remedy for angitis |
| 01/10/2007 | CN1893975A Medicament comprising inhibitors of long pentraxin ptx3 |
| 01/10/2007 | CN1893974A Immunogenic compositions |
| 01/10/2007 | CN1893973A Methods for porducing storage stable viruses and immunogenic compositions thereof |